Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides
on April 16, 2018 at 7:46 am
report on the new technology in Nature Communications, in a paper entitled “Incorporation of Bridged Nucleic Acids into CRISPR RNAs Improves Cas9 Endonuclease Specificity.” The CRISPR-Cas9 system has become a key genome-editing tool that has widespread ... […]
Breakthrough CRISPR Gene Editing Trial Set to Begin This Year
on April 16, 2018 at 3:08 am
Also known as CRISPR-Cas9, it was inspired by genetic defense mechanisms ... beta thalassaemia will become the first human disease treated with CRISPR gene-editing technology in Europe. A specific location for the first trial has not yet been announced. […]
ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services
on November 9, 2017 at 4:00 pm
ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual ... into a breakthrough gene editing technology. […]
Syngenta obtains non-exclusive IP license from Broad Institute for CRISPR-Cas9 genome-editing technology for agriculture applications
on November 1, 2017 at 5:00 pm
Syngenta announced today it has attained a non-exclusive IP license from the Broad Institute of MIT and Harvard for CRISPR-Cas9 genome-editing technology for agricultural applications. CRISPR-Cas9 genome editing technology complements Syngenta’s already ... […]
Intellia Therapeutics : Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study
on September 27, 2017 at 5:14 am
(GlobeNewswire) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today presented the full 12-month data of its completed long-term ... […]
Genome Editing with CRISPR-Cas9 Prevents Angiogenesis of the Retina
on July 24, 2017 at 2:05 pm
In a report published online today in Nature Communications, the researchers present a novel gene-editing technique ... to impaired vision. CRISPR-Cas9 is a powerful new technology that can target and edit certain aspects of the genome, or the complete ... […]
via Google News and Bing News